BP is a rare autoimmune blistering skin disease that typically affects individuals older than 65 years. Currently, there is no cure for BP. The US/EU market size is currently estimated at 60,000 patients. The addressable global market for Bertilimumab in BP could reach $1.6 billion.
Crohn's disease and ulcerative colitis are debilitating chronic inflammatory diseases of the digestive tract. The estimated market for biologics in moderate-to-severe IBD patients is estimated to grow to $10 billion.
Our lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid. Other indications considered for Bertilimumab development include atopic dermatitis, Crohn's disease, severe asthma and inflammatory liver diseases (NASH).
Learn More »